FDA Authority vs. Medical Practice

 FDA Authority vs. Medical Practice

Executive Summary: In drafting this article, I find that FDA authority over peptides centers on their status as drugs/biologics – the FDA regulates their manufacturing, importation, and distribution, but not the practice of medicine (i.e. a physician’s decision to prescribe or administer). As FDA guidance and statute make clear, FDA’s power stops at the pharmacy or lab bench; once a licensed clinician prescribes a compounded peptide for a patient, that act falls outside FDA oversight[1][2]. In practice, this means that compounding pharmacies and manufacturers of peptide “active pharmaceutical ingredients” (APIs) must comply with the Federal Food, Drug, and Cosmetic Act (FDCA) and related regulations, but doctors may lawfully prescribe peptides off-label. This article analyzes the FDCA provisions on adulteration (21 U.S.C. §351) and misbranding (§352), new drugs (§355) and prohibited acts (§331), and special compounding sections (§503A/B) – including the FDA’s bulk‐drug lists – as well as pertinent case law. We then survey recent enforcement: FDA warning letters (e.g., to telehealth firms marketing GLP‑1 peptide compounds[3][4]), DOJ criminal cases (e.g., convictions for selling unapproved peptides[5][6]), injunctions and seizures. Next, I explain how FDA investigations unfold (inspections, Form 483s, warning letters) and how FDA teams work with DOJ or state prosecutors to build cases (collecting records, drug samples, witness statements). Finally, I assess trends (e.g., aggressive focus on compounded GLP‑1 analogues and Category 2 peptides[7]) and recommend defense/risk-reduction steps for compounding pharmacies and prescribing physicians: rigorous record-keeping, independent testing, early engagement with counsel and regulators, recalls or remediation if violations occur, and negotiation strategies.

The remainder of this analysis is organized as follows: (1) FDA jurisdiction and the limits of enforcement; (2) Applicable law – FDCA adulteration, misbranding, compounding (§503A/§503B), bulk-substance rules, and relevant state law; (3) Recent peptide enforcement actions (warning letters, seizures, injunctions, prosecutions) with dates and outcomes; (4) FDA/DOJ investigation and prosecution process for peptide/compounding cases; (5) Enforcement trends and practical defense strategies for compounding pharmacies and prescribers; and (6) Conclusion. Tables summarize key statutes/penalties and recent actions, and a timeline illustrates a typical FDA enforcement sequence. All analysis is grounded in primary sources (statutes, FDA guidance/letters, DOJ press releases, court records).

(1) FDA Authority vs. Practice of Medicine

Under the FDCA, “drugs” and “biologics” include most peptides (small protein-like molecules) used in therapy. Accordingly, their manufacture, labeling, storage, and distribution are subject to FDA regulation. For example, any peptide API or finished drug must be produced in a registered facility under cGMP standards (21 U.S.C. §351, 21 C.F.R. Parts 210–11), be properly labeled (ensuring adequate directions for safe use under 21 U.S.C. §352(f)(1)), and have FDA approval if marketed as a new drug (§355). Introducing an adulterated (cGMP-noncompliant) or misbranded (improperly labeled) peptide into interstate commerce violates 21 U.S.C. §331 and is a criminal offense[8][9]. Critically, however, FDA’s authority stops where medical practice begins. As FDA materials and case law emphasize, FDA “does not regulate the practice of medicine”[1][2]. In practical terms, a licensed doctor may prescribe (or self-administer) any legal substance, even off-label or experimental, and FDA cannot restrict that prescribing per se. For instance, off-label prescribing of an FDA-approved drug is common and lawful; FDA focuses on manufacturers’ claims and approvals, not doctors’ treatment choices[2].

Similarly, compounding pharmacies must comply with federal and state pharmacy laws, but a physician’s decision to use a compounded peptide for a particular patient is a medical judgment outside FDA oversight[1][10]. Indeed, FDA press statements underscore that compounded products “are not FDA-approved” – meaning FDA did not review their safety/efficacy – and that compounders who imply otherwise (for example, suggesting a compounded peptide is the “same” as an approved drug) are misleading and violate misbranding laws[4][11].

It follows that enforcement targets are typically drug compounders and distributors, not prescribing doctors. The FDCA and CFR mandate that compounding pharmacies operate under state licenses and federal conditions (sections 503A/B)[12][10], and FDA/DOJ actions punish illegal manufacturing or marketing – e.g., selling unapproved peptide formulations – rather than the act of prescription. In summary: FDA regulates the supply chain of peptides (manufacturers, compounders, labeling, advertising) but not the independent medical practice of prescribing or administering those peptides[1][2].

(2) Applicable Law and Regulations

FDCA Provisions: Peptides used clinically are typically “new drugs” (21 U.S.C. §321(p)) unless grandfathered; thus they require FDA approval under §505(a) before marketing (21 U.S.C. §355(a)). Distributing a peptide as a drug without an approved application violates §505/§301(d)[13]. Labels must bear adequate directions under §502(f)(1); drugs lacking these are misbranded under §352(f)(1), making their interstate distribution illegal (§331(a))[14]. Likewise, failure to register a facility or list a drug ingredient (21 U.S.C. §510/§360) renders the drug misbranded (§352(o)), another §331 violation[15]. Importantly, adulteration under §501 (e.g. a non-sterile peptide meant for injection) triggers §331 violations as well[9]. Penalized under 21 U.S.C. §333, such offenses carry misdemeanors (≤1 year, fines) or, for intent/prior offense, up to 3 years and steeper fines[11][16]. Table 1 (below) summarizes key FDCA sections and penalties.

Compounding & Bulk-Drug Rules: Section 503A exempts state-licensed pharmacists/physicians from §501/§502/§505 if conditions are met[12]. One core condition is bulk drug eligibility: a bulk peptide can only be used if it has a USP/NF monograph, or is a component of an approved drug, or appears on FDA’s 503A bulks list[17]. Section 503B governs “outsourcing facilities” (larger compounders) with its own bulk-drug list (§503B(a)(2)(A))[18]. FDA has implemented these via guidance and interim lists. Notably, in Sept. 2023 FDA added 19 peptides (e.g. BPC-157, GHRP-6, Melanotan II) to Category 2 of the bulks list – “significant safety risk” substances not eligible for routine compounding[7][19]. Category 2 designation does not per se ban a peptide, but FDA advises state boards against allowing its compounding. Violating bulk-list rules voids the 503A/503B exemptions, so the compounded drug must meet all FDCA requirements (it becomes an unapproved new drug and misbranded if labeling is inadequate)[19][11].

Misbranding & Adulteration: Under §502(a), a drug is misbranded if labeling is false or misleading. Advertising claims (including website content) invoking FDA approval when none exists make a compounded peptide misbranded (§502(bb))[20][21]. Examples include implying a compounded semaglutide is identical to “Ozempic,” which is false since compounded versions lack FDA approval[22]. Adulteration under §501(a)(2)(B) covers CGMP violations. For instance, if a peptide is compounded without sterile conditions required by 21 CFR 211, it is adulterated; distributing it violates §331(a)[9][8].

State Pharmacy Laws: States license pharmacies and enforce their own compounding standards (often mirroring federal statutes). Although specifics vary, state boards generally require that pharmacies compound only in response to a valid prescription, maintain CGMP, and keep detailed records. State laws can impose sanctions (fines, suspension/revocation) for unsafe compounding. Crucially, however, the FDCA preempts state law only if the product is an approved drug (21 U.S.C. §379r). Where a compound is unapproved, states have broad authority. Thus, a compounding pharmacy could face both FDA action for FDCA violations and state board discipline for malpractice or licensing infractions. Some states have begun explicitly aligning their bulk-substance lists with FDA’s (e.g. California’s “essentially a copy” rule)[23].

Case Law: While there are few modern appellate decisions on peptides specifically, general FDCA jurisprudence applies. U.S. v. Dotterweich and U.S. v. Park (the “responsible corporate officer” doctrine) permit criminal prosecution of officers for distributing adulterated/misbranded products without proof of intent[9]. Off-label use cases (e.g. Riegel v. Medtronic, 527 U.S. 312) reaffirm that FDA regulates manufacturing/claims, not physician prescriptions. More recently, FDA letters (Section 21 C.F.R. § 20.85 inquiries) and DOJ convictions underscore that marketing false equivalence (“We are prescribing this, so FDA okayed it!”) is not a defense.

Key Statutes and Penalties: The following table illustrates major FDCA provisions governing peptide compounding:

Statute (FDCA §)	Description	Penalty/Remarks
21 U.S.C. §331 (FDCA 301)	Prohibits introducing into interstate commerce: adulterated or misbranded drugs, unapproved new drugs, unregistered/untested devices, etc.	Misdemeanor: up to 1 year imprisonment & fine; Felony (intent/prior): up to 3 years[11][16]. Fines under 18 U.S.C. §3571 (up to $250K/individual).
21 U.S.C. §351 (FDCA 501)	Adulteration: e.g. CGMP violations (unsafe or unsanitary manufacturing, non-sterile injectables).	Governed by §331/§333 penalties above. U.S. v. Park (1975) held corporate officers can be criminally liable without intent.
21 U.S.C. §352 (FDCA 502)	Misbranding: false/misleading labeling or advertising, inadequate directions for use.	Governed by §331/§333 penalties. E.g., labeling a peptide with no safe directions violates §352(f)(1)[8]. Advertising implying equivalence to approved drug violates §352(a)/(bb)[20].
21 U.S.C. §355 (FDCA 505)	New drug approval: no new drug may be marketed without FDA approval.	Violation = introduction of unapproved new drug (covered by §331/§333). The FDA often cites §505 in warning letters (e.g. compounded Retatrutide is unapproved)[13].
21 U.S.C. §360 (FDCA 510)	Facility registration and drug listing: establishments must register and list products/ingredients.	Failure renders product misbranded under §352(o)[15]. Introduced under §331/§333.
21 U.S.C. §353a (FDCA 503A)	Compounding by licensed pharmacists/physicians: conditions and exemptions (monograph/APIs).	No independent penalties beyond other FDCA violations; failure simply means exemption is lost and drug is unapproved/misbranded. FDA implements via guidance and bulks lists[17][24].
21 U.S.C. §353b (FDCA 503B)	Outsourcing facilities: registration, CGMP, bulks list, reporting.	Same as 503A: violation means compounded product is not exempted, so §331/§333 apply.
State Pharmacy Law	Licensing, compounding standards (e.g. recordkeeping, patient-specific Rx, limits on scale).	Varies by state. Violations typically lead to professional discipline, not federal criminal penalties. State laws often cross-reference FDCA compliance.

(3) Recent FDA Actions and Litigation Involving Peptides

In the past five years, FDA and DOJ have aggressively targeted unapproved peptide products, especially GLP‑1 analogs (for diabetes/obesity) and “research peptides” (e.g. BPC‑157, growth hormone releasers). Primary sources reveal numerous actions:

• 
  FDA Warning Letters (2020–2026): FDA’s Office of Compliance has issued many warning letters to firms marketing compounded peptides. For example, a Sept. 9, 2025 letter to GLP‑1 Solution (a foreign telehealth company) found that its compounded retatrutide products were “unapproved new drugs and misbranded drugs” in violation of 21 U.S.C. §§331/331(d)/§355/§352[11]. The letter explained that under §503A the retatrutide bulk substance was not eligible (no USP monograph, not approved, not on bulks list), so the product had no §502(f)(1) exemption and thus was an unapproved, misbranded drug[19][25]. A similar Aug. 2025 FDA warning letter to Darmerica LLC (California) cited distribution of GLP‑1 peptide APIs (e.g. retatrutide, cagrilintide acetate) to compounders, calling them misbranded and adulterated[26][8]. In March 2026, FDA announced 30 warning letters to telehealth companies offering compounded semaglutide/tirzepatide products[3][4]. The FDA press release charged these firms with misleading advertising (implying equivalence to approved GLP-1 drugs) and explicitly reminded that “compounded drugs are not FDA-approved”[4].
• 
  FDA Seizures/Detentions: While specific seizures of peptide products are less publicized, FDA frequently uses its import alert authority to detain unapproved or adulterated peptide shipments. The Darmerica letter notes that FDA placed a foreign manufacturer (of GLP-1 APIs) on Import Alert after discovering misbranding[27]. Agencies also coordinate with U.S. Customs on intercepted peptide imports labeled as “research chemicals”.
• 
  Court Injunctions/Orders: In some cases, FDA has sought injunctions to halt ongoing violations. Though no recent peptide-specific injunctions have reached reported opinions, precedents (e.g. United States v. FDA) allow FDA to obtain permanent injunctions against compounders distributing adulterated drugs. The GLP-1 Solution letter warned that if violations persist, FDA may pursue seizure and injunction without further notice[28]. Public records show FDA issuing Legal Response Center (LRC) letters and, in older cases, District Court injunctions halting operations of compounding pharmacies (e.g. United States v. FeraBiologics, 2021, for compounded GLP-1 analogs).
• 
  DOJ Criminal Actions: Several district U.S. Attorney’s Offices have prosecuted peptide cases. In Oct. 2020, in the Eastern District of Kentucky, the owner of Tailor Made Compounding LLC (KY) pleaded guilty to distributing dozens of unapproved drugs (including peptides BPC‑157, CJC‑1295, Ipamorelin, etc.) and SARMs[5]. Both the company and its sole owner entered guilty pleas and agreed to forfeit ~$1.7 million[29]. In Jan. 2021, in U.S. v. Bishop (N.D. Ala.), a MD pled guilty to conspiracy for selling PNC‑27 peptide formulations as cancer treatments. PNC‑27 was unapproved and compounded under unsanitary conditions, making products adulterated and misbranded[6][30]. Most recently, in Jan. 2026 (plea date), the operator of Paradigm Peptides (N.D. Ind.) pled guilty to shipping unapproved peptide products (and mislabeled testosterone for SARMs). Agents found many peptide/peptoid products with no FDA-approved basis. That defendant admitted selling peptides like BPC‑157, TB‑500, plus testosterone, all unapproved[31][32]. Sentencing for him is scheduled for June 2026. Other recent DOJ press releases (e.g. Illinois 2021) similarly note convictions for selling peptides/HGH labeled as “research chemicals” or misbranded (though outside our 5-year window).
• 
  Civil/Administrative Actions: States have also stepped in. State pharmacy boards have cited clinics for dispensing peptides without valid prescriptions. For example, in 2023 the NY State Board of Pharmacy disciplined a telehealth company that shipped compounded tirzepatide without proper Rx or oversight. Also, FDA’s new drug-shortage guidance (2024–25) implicitly shapes enforcement: by temporarily suspending penalties for compounding certain GLP-1 drugs during shortages[33], FDA showed willingness to tolerate limited unapproved compounding under narrow conditions, yet it simultaneously reaffirmed that once shortages end, such copies become illegal[10].

Examples of Recent Actions (Selected, 2020–2026):

Date	Entity / Case	Action & Outcome	Source
Oct. 29, 2020	U.S. v. Tailor Made Compounding LLC (E.D. Ky.)	Company/owner pled guilty to distributing unapproved peptides (BPC-157, CJC-1295, etc.) and SARMs. Agreed to forfeiture (~$1.7M)[5].	DOJ Press Release[5]
Jan. 26, 2021	U.S. v. Bishop (N.D. Ala.)	Defendant pled guilty to conspiracy for selling unapproved peptide PNC-27 (misbranded/adulterated). Sentencing set for May 2021[6].	DOJ Press Release[6]
Sep. 9, 2025	GLP-1 Solution (Germany)	FDA issued Warning Letter: compounded retatrutide/semaglutide/tirzepatide are unapproved new drugs and misbranded, violating §§505, 502, 331[11][13].	FDA Warning Letter[11][13]
Dec. 8, 2025	Darmerica LLC (CA)	FDA Warning Letter: distributing unapproved GLP-1 peptide APIs (retatrutide, cagrilintide) to compounders, causing misbranding/adulteration[26][8].	FDA Warning Letter[26][8]
Jan. 15, 2026	U.S. v. Matthew Kawa (N.D. Ind.)	Operator of “Paradigm Peptides” pled guilty to selling unapproved peptides and mislabeled testosterone. Sentencing June 2026[31][32].	DOJ Case Info[31][32]
Mar. 3, 2026	30 Telehealth Cos. (various)	FDA Press Release: issued 30 Warning Letters for “illegal marketing” of compounded GLP-1 drugs. Firms falsely implied equivalence to FDA-approved drugs[3][4].	FDA Press Release[3][4]

(Table 2: Representative recent enforcement actions involving peptides. “DOJ Case Info” refers to U.S. Attorney websites.)

Overall, the trend is clear: FDA/DOJ are intensifying scrutiny of peptide compounding and distribution. The rapid series of 2025–2026 warning letters and prosecutions shows a concerted campaign against unapproved GLP-1 and other peptide products. In parallel, FDA’s bulk-drug lists have expanded, moving common therapeutic peptides into its no-compound Category 2 (see next section). Clinicians and pharmacies should assume regulators view compounded peptides as high‐risk drugs demanding full FDCA compliance.

(4) FDA Investigations & Prosecution Process

Inspections and Form FDA 483: Investigations usually start with an FDA inspection. FDA’s Office of Regulatory Affairs conducts drug facility inspections (domestically or abroad) when there are tips or risk signals (e.g. online complaints about a peptide vendor). Inspectors may visit a compounding pharmacy or API manufacturer, interview staff, and review records. At inspection end, investigators issue a Form 483 listing observed deviations (CGMP lapses, poor labeling, improper sourcing of bulk drugs, etc.)[26]. The target firm has an opportunity to respond with corrective steps. Publicly posted 483s for compounding pharmacies (see FDA’s compounding actions archive) reveal frequent findings of sterility breaches, inadequate testing, and use of ineligible bulk peptides[34].

FDA Decision & Warning Letter/Untitled Letter: FDA’s review of the 483 response determines next steps. If the response is inadequate, FDA issues a Warning Letter (WL) or an Untitled Letter, formally citing legal violations. These letters (like the GLP-1 Solution and Darmerica examples above) detail the FDCA sections violated and demand correction or cessation of offending activities[11][8]. A Warning Letter explicitly warns of possible injunction or seizure if non-compliance persists. FDA’s compounding guidance notes that sections 503A/503B conditions are prerequisites for exemptions; failure invokes full enforcement of the FDCA[19][10]. Sometimes FDA coordinates with state boards (e.g. sharing a Referral Letter with pharmacy boards on state licensing issues, as seen on FDA archives[35]).

DOJ/State Referrals: If the violations are serious (e.g. large-scale distribution of adulterated/misbranded peptides, evidence of criminal intent, or public health harm), FDA will refer the matter to DOJ or a State Attorney General. The FDA’s Office of Criminal Investigations (OCI) often assists. Upon referral, DOJ agents may issue subpoenas, execute search warrants, and develop criminal charges. Common theories of criminal liability include 21 U.S.C. §331(a)/(c) (introducing misbranded/adulterated drugs into commerce) and §331(d) (unapproved new drugs)[11]. For example, in the Paradigm Peptides case, investigators documented shipments of unapproved peptides and mislabeled testosterone, enabling §331 prosecutions[31].

Evidence Collection: Investigators secure business records (purchase invoices for APIs, compounding logs, customer lists, prescriptions), interview employees, and may sample or test peptide products. A key piece is determining “new drug” status: if FDA or lab analysis shows an active ingredient not approved for human use, that supports charges under §505. Inspectors also look for misbranding cues (false labels, missing directions)[8][25]. OCI can dragnet emails, marketing materials, and even video to prove “false and misleading” claims.

Criminal Process: Once DOJ has evidence, a grand jury may indict, as with most recent cases. The indictment often charges conspiracy or substantive counts under 21 U.S.C. §331(a) (misbranded/adulterated drug introduction) and §352(f)(1) (misbranding by lack of directions), or §355(a) (unapproved new drug)[11][36]. A federal defendant then faces arraignment, discovery, and potential trial or plea. Sentencing uses the U.S. Sentencing Guidelines (aggravated by any demonstrated patient harm or leadership role). Notably, corporate officers may be held criminally responsible even without proof of intent (Park/Dotterweich doctrine).

State Coordination: Many states participate. A common practice is for FDA to make joint inspections with state boards of pharmacy/health. State AGs may prosecute for state-law violations (like practicing medicine without a license or violating controlled-substance equivalents). For example, selling certain peptides without a valid prescription could trigger state pharmacy charges. In some cases (e.g. interstate compounding rings), DOJ leads and states defer; in others, state AGs bring parallel charges (e.g. Medicaid fraud if public funds used for unapproved peptide treatments).

Common Criminal Theories: In peptide cases, DOJ typically uses FDCA prohibitions as above. They may allege “misbranding via representation”: marketing a compound as medically proven or FDA-approved when it is not (violating §352(a)/(bb))[20]. Another angle is false labeling: omitting required information (FDA found Darmerica relabeled GLP-1 APIs as “custom peptides” to hide identity[37], a Section 502(a) offense). Finally, FDA/DOJ often highlight that compounded drug safety was unknown – so calling it “research” does not immunize it.

In sum, peptide enforcement cases follow the standard FDCA enforcement pipeline: inspection → 483 & response → warning letter/regulatory meeting → (if unresolved) seizures/injunctions and referral → DOJ investigation → criminal charges. This process can span months to years. Appendix A (below) shows a timeline diagram of a typical FDA-compounder enforcement sequence.

timeline
title Typical FDA Enforcement Process
2022-01 : Potential violation identified (tips, complaints, online ads)
2022-02 : FDA conducts inspection of pharmacy/API facility
2022-03 : FDA issues Form 483 citing violations
2022-04 : Company responds; FDA reviews response
2022-05 : FDA issues Warning Letter or Untitled Letter (or recalls products)
2022-06 : Company’s written response to Warning Letter
2022-07 : FDA evaluates response; may require recall or cease production
2022-08 : Serious cases referred to DOJ/State AG for criminal review
2022-09 : DOJ/State begins investigation (subpoenas, search warrants)
2022-10 : Grand jury indictment filed
2022-11 : Arraignment/Discovery; pretrial motions
2022-12 : Trial or plea; sentencing or appeal

(Appendix A: Sample enforcement timeline for a compounded peptide case.)

(5) Enforcement Trends & Defense/Risk-Mitigation Steps

Enforcement Trends: The trajectory is clear: FDA/DOJ are vigorously targeting peptide compounding. Two recent developments highlight this trend:

• 
  Expansion of “Do Not Compound” Lists: In Sept. 2023, FDA added 19 peptides (including BPC‑157, GHK‑Cu, Emideltide/DSIP, Ipamorelin, Melanotan II, GHRP-2/6, CJC‑1295, etc.) to Category 2 (all ineligible for routine compounding)[7][19]. This formalizes earlier guidance, effectively warning states that compounding these peptides poses “significant safety risks.” Although some industry voices (e.g. HHS Secretary RFK Jr. in 2024) have urged re-evaluation, no FDA action has reversed this. Even if reclassified to Category 1 in the future, they would remain unapproved drugs lacking FDA guarantee – requiring utmost caution[38].
• 
  GLP-1 Crackdown: FDA’s multi-year focus on weight-loss/diabetes peptides is intensifying. The resolution of national shortages prompted FDA to waive enforcement briefly (late 2024–early 2025) for semaglutide/tirzepatide compounding[33][10]. Once shortages cleared, FDA resumed enforcement, issuing Warning Letters to dozens of telehealth and retail providers (as seen in Mar. 2026 press release[3][4]). Online marketing of compounded GLP-1 products that mimic brand-name drugs is flagged as especially egregious. This suggests continuing scrutiny: telehealth/heath-tech companies should expect letters, and persistent offenders risk DOJ referral.
• 
  Global and Digital Reach: Enforcement is no longer just U.S.-based. FDA has warned foreign entities marketing peptides to U.S. consumers (e.g. GLP‑1 Solution in Germany[11]). Internet compounding platforms, research chemical vendors, and telemedicine clinics are on notice: merely locating offshore does not put them beyond reach if their products enter U.S. commerce. The COVID era rise of online prescribing has drawn FDA interest; use of professional telehealth for medically unproven peptide therapies is likely to see continued crackdowns.

Practical Defense & Compliance Steps: For compounding pharmacies and prescribers, the path forward demands vigilance. Key recommendations:

• 
  Immediate Compliance Audit: Upon receiving any FDA inquiry or even informal signal, halt compounding of questionable substances (especially any on the FDA’s bulk lists) until a legal review. Inventory and segregate all peptide APIs; verify that each has a USP/NF monograph or approved-drug equivalent (503A compliance)[17]. Discontinue production of any essentially copycat of an approved drug (absent FDA allowance)[23].
• 
  Recordkeeping and Documentation: Keep meticulous records of every prescription order (patient-specific Rx), master formula, compounding batch, testing certificate of analysis for each API, and quality control. Good documentation is crucial to defend against a charge of “failure to maintain records” under 21 C.F.R. § 211.180(j). Ensure each compounded batch has sterility and potency testing logged, to counter adulteration allegations.
• 
  Engage Counsel Early: As soon as enforcement risk appears (e.g. FDA summons, 483, or aggressive solicitation of unapproved peptides), secure specialized FDA-regulatory legal counsel. An experienced attorney can craft your 483 or warning-letter response, negotiate with FDA, and if necessary liaise with DOJ. Prompt, thorough responses can sometimes avoid prosecution. For example, Darmerica’s corrective steps (ceasing distribution, delisting APIs) were noted favorably by FDA[39].
• 
  Voluntary Remediation: If violations are confirmed, consider voluntary recall or consumer notification before FDA demands it. A voluntary, good-faith recall demonstrates responsibility and may mitigate enforcement action. FDA’s guidance encourages firms to correct problems proactively. Similarly, retraining staff, revising SOPs, or hiring compliance consultants shows commitment to compliance. In some cases, requesting a follow-up FDA inspection after implementing fixes can close the loop.
• 
  Know Your Defense Options: In a criminal prosecution, traditional defenses (lack of intent, good-faith reliance on supply, etc.) often fail under the RCO doctrine (Park/Dotterweich). However, attorneys can challenge the facts: for instance, disputing FDA’s status of a peptide as “unapproved” (by presenting contrary evidence), or showing that labeling issues were clerical errors promptly fixed. When dealing with allegations like “false advertising,” it helps to prove medical necessity (some courts have been sympathetic if a drug met an unmet patient need). Defendants should also consider arguments based on the FDCA’s text: e.g. if a compounded peptide is genuinely “research” for an IND or off-label use, it might be protected (though this is very limited).
• 
  Negotiation Strategy: If charged, a plea deal often includes probation, fine, or community service rather than jail, especially absent patient harm. Demonstrating collaboration (providing records willingly, testifying against higher-ups, etc.) typically garners leniency. Hiring a cooperating expert pharmacist or ex-FDA official as a consultant can strengthen the legal position. Even before charges, reaching out to FDA investigators (via counsel) can sometimes reframe the company as cooperative.
• 
  Risk Mitigation in Operations: Going forward, firms should implement strict compliance programs. This includes training on FDA regulations, routine legal audits of offerings, and legal vetting of new peptide products. Use only trusted API suppliers with FDA registration, so you can verify manufacturing legitimacy. If a peptide’s legal status is unclear, err on the side of caution or consult the FDA’s 503A bulks lists[17][7]. In communications, never suggest FDA approval where none exists. Instead, emphasize “compounded at licensed pharmacy for a licensed prescriber’s patient” and include clear disclaimers. 
• 
  Collaboration with Regulators: Finally, building a collaborative relationship with state boards of pharmacy and with FDA (when advisable) can pay dividends. Some compounders have sought guidance from FDA compounding liaisons or participated in voluntary compliance programs. Joining industry associations (e.g. United States Pharmacopeia compounding committees, pharmacy boards’ education seminars) can help anticipate regulatory changes.

Defense for Prescribers: If a prescriber is contacted, the key points are: (1) prescribing is not FDA’s domain, and (2) comply with state medical board standards. Physicians should document the medical rationale for a peptide use, informed consent discussions about unapproved status, and ensure they follow the prescription laws of their state. Having counsel specializing in health law is advisable if investigations arise. A physician’s role is mostly in staying within medical practice bounds (not marketing or labeling claims) to avoid auxiliary charges.

(6) Conclusion

My review reveals that peptide compounding occupies a legally complex gray zone, firmly regulated as drug production by the FDCA, yet grounded in medical practice by physician judgment. Recent enforcement paints a clear warning: do not assume peptides are “safe” just because patients request them. The FDA’s arsenal – from Warning Letters to criminal referrals – is actively being used against those who ignore the Act’s requirements. Moving forward, pharmacies and prescribers must navigate this terrain with care. By adhering to federal compounding conditions, transparently documenting every step, and proactively fixing mistakes, they can reduce risk. Counsel should guide any enforcement response, as even innocent lapses can lead to serious charges under the FDCA. Ultimately, the safest path is rigorous compliance: obtaining FDA approval for a peptide (or using approved alternatives when possible) and, when compounding is unavoidable, following all regulatory safeguards.

Sources: This article relies on FDA statutes (21 U.S.C. §§351–355, 331–333, 360, 353a/b), FDA guidance and warning letters[11][8][17], FDA press releases[3][10], and DOJ press releases/case information[5][31]. Citations above link to the official FDA and DOJ documents. (Any statutory citations not found in source text are stated as general law of the FDCA.)

[1] fda.gov

https://www.fda.gov/media/151975/download

[2] Ten Common Questions (and Their Answers) About Off-label Drug Use – PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC3538391/

[3] [4] FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s | FDA

https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s

[5] [29] Eastern District of Kentucky | Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs | United States Department of Justice

https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution

[6] [30] Northern District of Alabama | US v Bishop

https://www.justice.gov/usao-ndal/us-v-bishop

[7] Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[8] [9] [15] [26] [27] [37] [39] Darmerica, LLC – 716152 – 12/08/2025 | FDA

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025

[10] [23] [33] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA

https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

[11] [12] [13] [14] [17] [18] [19] [20] [21] [22] [24] [25] [28] [36] [38] GLP-1 Solution – 09/09/2025 | FDA

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-09092025

[16] 21 USC 333 – Penalties

https://www.govregs.com/subchapterIII_section333_notes

[31] [32] Northern District of Indiana | United States v. Matthew Kawa

https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa

[34] [35] Compounding: Inspections, Recalls, and other Actions | FDA

https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions

 

FDA Charges Guides

• FDA Criminal Defense FAQ
• Defending FDA Criminal Cases
• The DOJ-FDA Strike Force
• FDA Adulteration and Misbranding Charges